Abstract
The immune system, which is indispensible for controlling neoplasias, relies on its innate and acquired immunity components to mount an effective response against tumors. In this context, dendritic cells (DCs) are seen as the best antigen-presenting cells because of their capacity for cross-presentation, which can activate both T-helper and cytotoxic lymphocytes. Thus immunotherapy with DCs is considered promising, especially for early-stage cancers. This article provides a clarifying review of recent perspectives on the development of cancer immunotherapy, which has a wide potential for therapeutic applications, and of patents related to immunotherapy with DCs.
Keywords: Cancer, dendritic cells, immunotherapy, immune response, therapeutic potential, tumor.
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery
Title:Immunotherapy with Dendritic Cells as a Cancer Treatment: Perspectives and Therapeutic Potential
Volume: 7 Issue: 3
Author(s): Andre A.R. Aleixo, Márcia A. Michelin and Eddie F.C. Murta
Affiliation:
Keywords: Cancer, dendritic cells, immunotherapy, immune response, therapeutic potential, tumor.
Abstract: The immune system, which is indispensible for controlling neoplasias, relies on its innate and acquired immunity components to mount an effective response against tumors. In this context, dendritic cells (DCs) are seen as the best antigen-presenting cells because of their capacity for cross-presentation, which can activate both T-helper and cytotoxic lymphocytes. Thus immunotherapy with DCs is considered promising, especially for early-stage cancers. This article provides a clarifying review of recent perspectives on the development of cancer immunotherapy, which has a wide potential for therapeutic applications, and of patents related to immunotherapy with DCs.
Export Options
About this article
Cite this article as:
Aleixo A.R. Andre, Michelin A. Márcia and Murta F.C. Eddie, Immunotherapy with Dendritic Cells as a Cancer Treatment: Perspectives and Therapeutic Potential, Recent Patents on Endocrine, Metabolic & Immune Drug Discovery 2013; 7 (3) . https://dx.doi.org/10.2174/18722148113079990001
DOI https://dx.doi.org/10.2174/18722148113079990001 |
Print ISSN 1872-2148 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3334 |
Related Articles
-
miRNAs in Bone Development
Current Genomics Indazolo[3,2-b]quinazolinones Attack Hepatocellular Carcinoma Hep3B Cells by Inducing Mitochondrial-Dependent Apoptosis and Inhibition of Nrf2/ARE Signaling Pathway
Current Molecular Medicine Design Graph Theoretical Analysis and In Silico Modeling of Dunaliella Bardawil Biomass Encapsulated N-Succinyl Chitosan Nanoparticles for Enhanced Anticancer Activity
Anti-Cancer Agents in Medicinal Chemistry AG490 Promotes HIF-1α Accumulation by Inhibiting Its Hydroxylation
Current Medicinal Chemistry Exploring and Exploiting Biologically Relevant Chemical Space
Current Drug Targets Artificial Neural Network as a Classifier for the Identification of Hepatocellular Carcinoma Through Prognosticgene Signatures
Current Genomics In vitro Measurement and In vivo Prediction of Time-Dependent Inhibitory Effects of Three Tyrosine Kinase Inhibitors on CYP3A Activity
Current Drug Metabolism Deregulation of the Mitochondrial Apoptotic Machinery and Development of Molecular Targeted Drugs in Acute Myeloid Leukemia
Current Cancer Drug Targets Small-Molecule Inhibitors Targeting eIF4A in Leukemia
Current Protein & Peptide Science Regulatory Overview of Biosimilars: Current Scenario and Future Opportunities
Applied Clinical Research, Clinical Trials and Regulatory Affairs Metal Based Frameworks for Drug Delivery Systems
Current Topics in Medicinal Chemistry The Chemopreventive and Chemotherapeutic Potentials of Tea Polyphenols
Current Pharmaceutical Biotechnology Aurora A and B Kinases - Targets of Novel Anticancer Drugs
Recent Patents on Anti-Cancer Drug Discovery Protein Kinase CK2 Inhibitors: Emerging Anticancer Therapeutic Agents?
Anti-Cancer Agents in Medicinal Chemistry Piecing the Fragments Together: Dynamical Insights into the Enhancement of BRD4-BD1 (BET Protein) Druggability in Cancer Chemotherapy Using Novel 8-methyl-pyrrolo[1,2-a]pyrazin-1(2H)-one Derivatives
Current Pharmaceutical Biotechnology Newer Insights in Personalized and Evidence Based Medicine- the Role of MicroRNAs
Current Pharmacogenomics and Personalized Medicine Clinical and <i>In Silico</i> Outcomes of the Expression of miR-130a-5p and miR-615-3p in Tumor Compared with Non-Tumor Adjacent Tissues of Patients with BC
Anti-Cancer Agents in Medicinal Chemistry The Synthesis, Anticancer Activity, Structure-Activity Relationships and Molecular Modelling Studies of Novel Isoindole-1,3(2H)-dione Compounds Containing Different Functional Groups
Anti-Cancer Agents in Medicinal Chemistry Dasabuvir: A Non-Nucleoside Inhibitor of NS5B for the Treatment of Hepatitis C Virus Infection
Reviews on Recent Clinical Trials Bile Acids as Novel Pharmacological Agents: The Interplay Between Gene Polymorphisms, Epigenetic Factors and Drug Response
Current Pharmaceutical Design